Literature DB >> 16617322

The JAK2 V617F mutation identifies a subgroup of MDS patients with isolated deletion 5q and a proliferative bone marrow.

W Ingram, N C Lea, J Cervera, U Germing, P Fenaux, B Cassinat, J J Kiladjian, J Varkonyi, P Antunovic, N B Westwood, M J Arno, A Mohamedali, J Gaken, T Kontou, B H Czepulkowski, N A Twine, J Tamaska, J Csomer, S Benedek, N Gattermann, E Zipperer, A Giagounidis, Z Garcia-Casado, G Sanz, G J Mufti.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16617322     DOI： 10.1038/sj.leu.2404215

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  12 in total

Review 1.  Mutation-Driven Therapy in MDS.

Authors:  David M Swoboda; David A Sallman
Journal:  Curr Hematol Malig Rep       Date:  2019-12       Impact factor: 3.952

2.  The prognostic impact of germline 46/1 haplotype of Janus kinase 2 in cytogenetically normal acute myeloid leukemia.

Authors:  Sarolta Nahajevszky; Hajnalka Andrikovics; Arpad Batai; Emma Adam; Andras Bors; Judit Csomor; Laszlo Gopcsa; Magdalena Koszarska; Andras Kozma; Nora Lovas; Sandor Lueff; Zoltan Matrai; Nora Meggyesi; Janos Sinko; Andrea Sipos; Andrea Varkonyi; Sandor Fekete; Attila Tordai; Tamas Masszi
Journal:  Haematologica       Date:  2011-07-26       Impact factor: 9.941

3.  JAK2 V617F mutation in myelodysplastic syndrome, myelodysplastic syndrome/myeloproliferative neoplasm, unclassifiable, refractory anemia with ring sideroblasts with thrombocytosis, and acute myeloid leukemia.

Authors:  Dong Wook Jekarl; Sang Bong Han; Myungshin Kim; Jihyang Lim; Eun-Jee Oh; Yonggoo Kim; Hee-Je Kim; Woo-Sung Min; Kyungja Han
Journal:  Korean J Hematol       Date:  2010-03-31

4.  Durable response to lenalidomide in a patient with myelodysplastic syndrome associated with isolated 5q deletion and JAK2 V617F mutation despite discontinuation of treatment.

Authors:  Eleftheria Hatzimichael; Konstantinos Lagos; Amalia Vassou; Dora Gougopoulou; Alexandra Papoudou-Bai; Evangelos Briasoulis
Journal:  Mol Clin Oncol       Date:  2016-04-20

5.  Differential gene expression of bone marrow-derived CD34+ cells is associated with survival of patients suffering from myelodysplastic syndrome.

Authors:  Wolf C Prall; Akos Czibere; Franck Grall; Dimitrios Spentzos; Ulrich Steidl; Aristoteles Achilles Nikolaus Giagounidis; Andrea Kuendgen; Hasan Otu; Astrid Rong; Towia A Libermann; Ulrich Germing; Norbert Gattermann; Rainer Haas; Manuel Aivado
Journal:  Int J Hematol       Date:  2009-01-20       Impact factor: 2.490

6.  Myeloid neoplasms with isolated del(5q) and JAK2 V617F mutation: a "grey zone" combination of myelodysplastic and myeloproliferative features?

Authors:  Valentina F I Sangiorgio; Julia T Geyer; Elizabeth Margolskee; Mustafa Al-Kawaaz; Susan Mathew; Wayne Tam; Attilio Orazi
Journal:  Haematologica       Date:  2019-09-26       Impact factor: 9.941

7.  WHO-defined 'myelodysplastic syndrome with isolated del(5q)' in 88 consecutive patients: survival data, leukemic transformation rates and prevalence of JAK2, MPL and IDH mutations.

Authors:  M M Patnaik; T L Lasho; C M Finke; N Gangat; D Caramazza; S G Holtan; A Pardanani; R A Knudson; R P Ketterling; D Chen; J D Hoyer; C A Hanson; A Tefferi
Journal:  Leukemia       Date:  2010-05-20       Impact factor: 12.883

Review 8.  Pathogenesis of myelodysplastic syndromes: an overview of molecular and non-molecular aspects of the disease.

Authors:  Valeria Visconte; Ramon V Tiu; Heesun J Rogers
Journal:  Blood Res       Date:  2014-12-23

9.  Prognostic impact of JAK2V617F mutation in myelodysplatic syndromes: A matched case control study.

Authors:  Benoit de Renzis; Veronique Mansat-De Mas; Eric Wattel; Odile Beyne-Rauzy; Laurent Knoops; Aurélie Cabrespine; Zahia Azgui; Lionel Ades; Jean-Jacques Kiladjian; Pierre Fenaux
Journal:  Leuk Res Rep       Date:  2013-08-30

Review 10.  Myelodysplastic disorders carrying both isolated del(5q) and JAK2(V617F) mutation: concise review, with focus on lenalidomide therapy.

Authors:  Pellegrino Musto; Vittorio Simeon; Roberto Guariglia; Gabriella Bianchino; Vitina Grieco; Filomena Nozza; Francesco La Rocca; Gioacchino Marziano; Anna Vittoria Lalinga; Emiliano Fabiani; Maria Teresa Voso; Patrizia Scaravaglio; Cristina Mecucci; Giovanni D'Arena
Journal:  Onco Targets Ther       Date:  2014-06-13       Impact factor: 4.147
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.